Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Aditum Bio Announces Formation of Vitalli Bio, Focused on Immunological Disorders
Aditum Bio, the biotech investment firm cofounded in 2019 by former Novartis CEO Joe Jimenez […]
Actinium Announces Positive Pivotal Phase 3 SIERRA Trial Results of Iomab-B Showcased to the European Transplant Community
Actinium Pharmaceuticals, a leader in the development of targeted radiotherapies, today announced that the positive […]
Brenus Pharma Unveils Groundbreaking Preclinical Results For STC-10101, a Promising New Drug Candidate Targeting Colorectal Cancer & Solid Tumors
Brenus Pharma announces two groundbreaking presentations on STC-1010, the company’s first drug candidate for colorectal […]
Avidity Biosciences Announces Positive Topline Data from Myotonic Dystrophy Trial
Avidity Biosciences, a biopharmaceutical company committed to delivering a new class of RNA therapeutics called […]
Editas Medicine Receives FDA Orphan Drug Designation for EDIT-301 for the Treatment of Sickle Cell Disease
Editas Medicine, a clinical stage genome editing company, today announced that the US Food and […]
RenovoRx Appoints Former Chief Medical Officer of Schering-Plough, Robert J. Spiegel, MD, FACP, to Board of Directors
RenovoRx, a biopharmaceutical company focused on targeted drug-delivery with an initial application in locally advanced […]
Antiva Biosciences Closes $53 Million Series E Equity Financing
Antiva Biosciences, a biopharmaceutical company developing novel, topical therapeutics for the treatment of pre-cancerous lesions […]
Therini Bio Raises $36M Series A Financing to Develop Fibrin-Targeted Therapies for Neurodegenerative and Retinal Diseases
Therini Bio, a biotech company aimed at developing fibrin-targeted therapies to treat inflammatory neurodegenerative and […]
Junshi Biosciences Announces Primary Endpoint Met in RENOTORCH Study of Toripalimab for 1st-line Treatment of Advanced Renal Cell Carcinoma
Shanghai Junshi Biosciences, a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization […]
Alnylam & Regeneron Report Positive Data on ALN-APP, an Investigational Therapeutic for Alzheimer’s Disease & Cerebral Amyloid Angiopathy
Alnylam Pharmaceuticals and Regeneron Pharmaceuticals announced today positive interim results from the ongoing single ascending […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more